Infectious Diseases and HIV Medicine
Publications
Comparative description of haplotype structure and genetic diversity of MDR1
Comparative description of haplotype structure and genetic diversity of MDR1
"Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations"
Infect Genet Evol. 2010 Jan
Benish RL, Rodriguez B, Zimmerman PA, Mehlotra RK.
Center for Global Health & Diseases, School of Medicine, Case Western Reserve University, Cleveland
Human P-glycoprotein (P-gp), encoded by MDR1 (ABCB1), is an efflux transporter with a wide specificity for substrates/drugs, including HIV protease inhibitors which are commonly used in HIV/AIDS treatment. Three single nucleotide polymorphisms (SNPs) in MDR1 have been shown to affect P-gp expression and function, and may affect HIV/AIDS treatment outcome: 1236C>T [G412G, exon-12], 2677G>T/A [A893S/T, exon-21] and 3435C>T [I1145I, exon-26]. In the present study, our aims were (i) to compare the 3-SNP MDR1 haplotype structure and genetic diversity between North American HIV-positive and HIV-negative individuals belonging to four major ethnic groups and (ii) to determine whether the haplotype structure and genetic diversity observed in these ethnically admixed populations differ from that in ethnically non-admixed populations. For these aims, we analyzed a cohort of 447 HIV/AIDS patients (White [n=193], Black [n=235], Hispanic [n=17], and Asian [n=2]). Results obtained for these patients were compared with the results for (i) HIV-negative individuals (n=356) and (ii) various HapMap and Environmental Genome Project populations. We observed that the genetic characteristics of MDR1 were largely consistent between HIV-positive and HIV-negative populations, but there were striking interethnic differences in the genetic characteristics of MDR1 in both populations. Although it appeared that the genetic characteristics of MDR1 were largely consistent between ethnically admixed and non-admixed populations, genetic characterization of the admixed populations remains to be done. Thus, our results provide useful comparative insights about the genetic characteristics of MDR1 that could be extrapolated across population groups worldwide. For a meaningful interpretation of these results regarding HIV/AIDS treatment outcome, MDR1 haplotype/diplotype structure data, genetic characterization of population admixture, and polymorphisms in other relevant drug transporter and/or metabolizing enzyme genes should be considered in future clinical studies.


- Division Chief Message
- Past Year in Review
- Publications
- Penicillin sulfone inhibitors of class D beta-lactamases
- In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates.
- Evaluation of an alcohol-based power sanitizing system
- Saline Nebulization before Gastric Lavage in the Diagnosis of Pulmonary Tuberculosis in Children and Adolescents
- Preserved MHC class II antigen processing in monocytes from HIV-infected individuals
- Acinetobacter baumannii-associated skin and soft tissue infections
- Streptococcus anginosus Pyomyositis in a 50-Year-Old Man with Acquired Immunodeficiency Syndrome
- Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes
- Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals
- Enhancing resistance to cephalosporins in class C beta-lactamases
- Three decades of beta-lactamase inhibitors
- In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates
- Persistence of skin contamination & environmental shedding of Clostridium difficile
- Comparative description of haplotype structure and genetic diversity of MDR1
- Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design
- Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase
- Increased tissue factor expression on circulating monocytes in chronic HIV infection
- Faculty
- Research
- The Fight Against TB
- Patient Care
- Fellowship Program
- Details
- Contacts